BioStack has raised $9.5 Million in New Funding
According to filings with the U.S. Securities and Exchange Commission, BioStack has raised $9,500,000.00 in new Seed funding. The federal securities law requires the notice to be filed by companies...
According to filings with the U.S. Securities and Exchange Commission, BioStack has raised $9,500,000.00 in new Seed funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
Investors in the company’s current round of funding include: Peak XV, Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, and Y Combinator
About BioStack
BioStack is a healthcare data company that sources and structures high-quality, machine-learning-ready datasets for artificial intelligence development. Its data spans electronic health records, laboratory results, medical imaging, ECGs, clinical notes, treatments, audio, and patient outcomes. BioStack provides novel pre-clinical and medical datasets, performs causal inference, annotates novel and public data, and generates data points for pre-training and post-training AI models. The company also supports reinforcement-learning environments, multi-agent reasoning infrastructure, and data-rich reward functions for healthcare AI applications. BioStack serves biotech startups, AI labs, and organizations seeking harder-to-find, context-rich healthcare data to build and improve industry-specific AI models using real-world clinical evidence.
To learn more, visit https://www.getbiostack.com/
Linkedin: https://www.linkedin.com/company/getbiostack/
Contact:
Sanat Mishra, CEO
https://www.linkedin.com/in/sanat-m/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.
No Comment! Be the first one.